Denali Therapeutics Inc (DNLI) is now in the Overvalued zone, suggesting that its current forward PS ratio of 199.57 is considered Overvalued compared with the five-year average of -12.38. The fair price of Denali Therapeutics Inc (DNLI) is between 3.41 to 11.73 according to relative valuation method. Compared to the current price of 21.00 USD , Denali Therapeutics Inc By Overvalued By 78.99%.

Relative Value

Fair Zone

3.41-11.73

Current Price：21.00

78.99%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Denali Therapeutics Inc (DNLI) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Denali Therapeutics Inc (DNLI) has a current Price-to-Book (P/B) ratio of 2.58. Compared to its 3-year average P/B ratio of 2.54, the current P/B ratio is approximately 1.40% higher. Relative to its 5-year average P/B ratio of 3.60, the current P/B ratio is about -28.42% higher. Denali Therapeutics Inc (DNLI) has a Forward Free Cash Flow (FCF) yield of approximately -16.17%. Compared to its 3-year average FCF yield of -13.18%, the current FCF yield is approximately 22.73% lower. Relative to its 5-year average FCF yield of -8.17%, the current FCF yield is about 98.01% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for DNLI competitors is 62.67, providing a benchmark for relative valuation. Denali Therapeutics Inc Corp (DNLI.O) exhibits a P/S ratio of 199.57, which is 218.47% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of DNLI increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of DNLI in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is DNLI currently overvalued or undervalued?

What is Denali Therapeutics Inc (DNLI) fair value?

DNLI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Denali Therapeutics Inc (DNLI) is between 3.41 to 11.73 according to relative valuation method.

How does DNLI's valuation metrics compare to the industry average?

The average P/S ratio for DNLI's competitors is 62.67, providing a benchmark for relative valuation. Denali Therapeutics Inc Corp (DNLI) exhibits a P/S ratio of 199.57, which is 218.47% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Denali Therapeutics Inc (DNLI) as of Mar 03 2026?

As of Mar 03 2026, Denali Therapeutics Inc (DNLI) has a P/B ratio of 2.58. This indicates that the market values DNLI at 2.58 times its book value.

What is the current FCF Yield for Denali Therapeutics Inc (DNLI) as of Mar 03 2026?

As of Mar 03 2026, Denali Therapeutics Inc (DNLI) has a FCF Yield of -16.17%. This means that for every dollar of Denali Therapeutics Inc's market capitalization, the company generates -16.17 cents in free cash flow.

What is the current Forward P/E ratio for Denali Therapeutics Inc (DNLI) as of Mar 03 2026?

As of Mar 03 2026, Denali Therapeutics Inc (DNLI) has a Forward P/E ratio of -5.51. This means the market is willing to pay $-5.51 for every dollar of Denali Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Denali Therapeutics Inc (DNLI) as of Mar 03 2026?

As of Mar 03 2026, Denali Therapeutics Inc (DNLI) has a Forward P/S ratio of 199.57. This means the market is valuing DNLI at $199.57 for every dollar of expected revenue over the next 12 months.

DNLI Valuation